Physician profile
Sandhya Jain
NPI 1023500972
$2,577.11
in general payments reported to CMS, 2019-2025
25 companies · $1,110 in 2025
The $1,110 reported for 2025 was more than what 88% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $129 · 2023: $543 · 2024: $794 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,447.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $696.12 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $267.44 | 2025 | Fanapt, Hetlioz |
| Abbvie INC. | $264.98 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $164.52 | 2022-2025 | Ingrezza |
| Lundbeck LLC | $127.00 | 2022-2024 | Rexulti |
| Pfizer INC. | $100.42 | 2023-2025 | |
| Uswm, LLC | $95.56 | 2023 | Lucemyra, Zimhi |
| Indivior INC. | $94.36 | 2024-2025 | Sublocade |
| Otsuka America Pharmaceutical, INC. | $86.79 | 2023-2024 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Alkermes, INC. | $76.13 | 2024-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $74.82 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $73.22 | 2023-2025 | Spravato |
| Exact Sciences Corporation | $71.84 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Actelion Pharmaceuticals US, INC. | $55.94 | 2023-2025 | Uptravi, Opsumit |
| Corium, LLC | $44.02 | 2023-2025 | Azstarys |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $42.77 | 2024-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $41.52 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $36.83 | 2022-2023 | Austedo |
| Sage Therapeutics, LLC | $34.90 | 2025 | Zurzuvae |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.35 | 2025 | Xifaxan |
| Viatris Specialty LLC | $26.85 | 2025 | Yupelri |
| Supernus Pharmaceuticals, INC. | $18.61 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $17.28 | 2022 | |
| Novo Nordisk INC | $16.77 | 2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $16.07 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandhya Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.